Cargando…

2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016

BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Estabrook, Mark, Kazmierczak, Krystyna, Stone, Gregory G, Sahm, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255069/
http://dx.doi.org/10.1093/ofid/ofy210.2101
_version_ 1783373871934603264
author Estabrook, Mark
Kazmierczak, Krystyna
Stone, Gregory G
Sahm, Dan
author_facet Estabrook, Mark
Kazmierczak, Krystyna
Stone, Gregory G
Sahm, Dan
author_sort Estabrook, Mark
collection PubMed
description BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in vitro activity of CAZ-AVI against Eba isolates from urinary tract infections (UTI), intra-abdominal infections (IAI) and lower respiratory tract infections (LRTI) gathered in Latin America (LA) from 2012 to 2016. METHODS: A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. Susceptibility testing was by broth microdilution using CLSI 2018 breakpoints. CAZ-AVI was tested with a fixed concentration of 4 µg/mL avibactam. Meropenem nonsusceptibility prompted β-lactamase screening by PCR and sequencing. RESULTS: CAZ-AVI demonstrated potent in vitro activity against Eba from UTIs, IAIs and LRTIs (99.6%, 99.8%, and 99.5% susceptible, respectively). CAZ-AVI was active against colistin-resistant and MDR Eba as well as meropenem-non-susceptible Eba not encoding metallo-β-lactamases (96.5%, 98.4% and 99.4% susceptible, respectively) (table). CONCLUSION: CAZ-AVI exhibited potent in vitro activity against Eba from UTIs, IAIs and LRTIs isolated in Latin America from 2012 to 2016 and provides a vital alternative to colistin and meropenem when MBLs are not present. DISCLOSURES: M. Estabrook, Pfizer, Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. K. Kazmierczak, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. G. G. Stone, Pfizer Inc.: Employee, Salary. AstraZeneca: Former Employee and Shareholder, Salary. D. Sahm, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary.
format Online
Article
Text
id pubmed-6255069
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62550692018-11-28 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016 Estabrook, Mark Kazmierczak, Krystyna Stone, Gregory G Sahm, Dan Open Forum Infect Dis Abstracts BACKGROUND: The dissemination of multi-drug-resistant Enterobacteriaceae (MDR Eba) threatens the treatment of Gram-negative infections. Ceftazidime–avibactam (CAZ-AVI) is a novel antimicrobial with activity against Eba producing Class A, C and some Class D β-lactamases. This study evaluates the in vitro activity of CAZ-AVI against Eba isolates from urinary tract infections (UTI), intra-abdominal infections (IAI) and lower respiratory tract infections (LRTI) gathered in Latin America (LA) from 2012 to 2016. METHODS: A total of 7,037 non-duplicate Eba were collected from UTI, IAI, or LRTI in 26 sites in 6 countries in LA, as a part of the INFORM surveillance study from 2012 to 2016. Susceptibility testing was by broth microdilution using CLSI 2018 breakpoints. CAZ-AVI was tested with a fixed concentration of 4 µg/mL avibactam. Meropenem nonsusceptibility prompted β-lactamase screening by PCR and sequencing. RESULTS: CAZ-AVI demonstrated potent in vitro activity against Eba from UTIs, IAIs and LRTIs (99.6%, 99.8%, and 99.5% susceptible, respectively). CAZ-AVI was active against colistin-resistant and MDR Eba as well as meropenem-non-susceptible Eba not encoding metallo-β-lactamases (96.5%, 98.4% and 99.4% susceptible, respectively) (table). CONCLUSION: CAZ-AVI exhibited potent in vitro activity against Eba from UTIs, IAIs and LRTIs isolated in Latin America from 2012 to 2016 and provides a vital alternative to colistin and meropenem when MBLs are not present. DISCLOSURES: M. Estabrook, Pfizer, Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. K. Kazmierczak, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. G. G. Stone, Pfizer Inc.: Employee, Salary. AstraZeneca: Former Employee and Shareholder, Salary. D. Sahm, Pfizer Inc.: Consultant, Consulting fee. IHMA, Inc.: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6255069/ http://dx.doi.org/10.1093/ofid/ofy210.2101 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Estabrook, Mark
Kazmierczak, Krystyna
Stone, Gregory G
Sahm, Dan
2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title_full 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title_fullStr 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title_full_unstemmed 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title_short 2448. In vitro Activity of Ceftazidime–Avibactam Against Enterobacteriaceae Causing Intra-abdominal, Urinary Tract and Lower Respiratory Tract Infections Collected in Latin America as Part of the INFORM Global Surveillance Program, 2012–2016
title_sort 2448. in vitro activity of ceftazidime–avibactam against enterobacteriaceae causing intra-abdominal, urinary tract and lower respiratory tract infections collected in latin america as part of the inform global surveillance program, 2012–2016
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255069/
http://dx.doi.org/10.1093/ofid/ofy210.2101
work_keys_str_mv AT estabrookmark 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016
AT kazmierczakkrystyna 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016
AT stonegregoryg 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016
AT sahmdan 2448invitroactivityofceftazidimeavibactamagainstenterobacteriaceaecausingintraabdominalurinarytractandlowerrespiratorytractinfectionscollectedinlatinamericaaspartoftheinformglobalsurveillanceprogram20122016